Search Results

You are looking at 111 - 120 of 1,412 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling

Alexander S. Baras, Jarushka Naidoo, Christine L. Hann, Peter B. Illei, Charles W. Reninger III, and Josh Lauring

(45 U/L). Fiberoptic bronchoscopy was performed with fine-needle aspiration (FNA) of a station 7 lymph node, and the pathology was read as poorly differentiated squamous cell carcinoma (SCC) ( Figure 2 ). Immunostains were positive for p63 and negative

Full access

Current Perspectives on Lymphatic Mapping in Carcinomas of the Uterine Corpus and Cervix

Robert L. Coleman, Michael Frumovitz, and Charles F. Levenback

versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study . Gynecol Oncol 1999 ; 72 : 177 – 183 . 12. Burke TW . Treatment

Full access

Point: Interferon-α for Adjuvant Therapy for Melanoma Patients

Michael S. Sabel and Vernon K. Sondak

Interferon-α is possibly the most controversial adjuvant therapy for any solid tumor, and multiple trials involving varying doses, routes, schedules, and formulations of interferon-α have increased the confusion. Clinicians are left in a quandary, because high-dose interferon-α-2b (HDI) remains the only FDA-approved adjuvant therapy for high-risk melanoma. Of the three prospective randomized trials involving high-dose interferon-α-2b, all show a significant improvement in disease-free survival and two show a significant improvement in overall survival. Despite this strong evidence, data from studies involving alternate doses, concerns regarding cost and toxicity, and the promise of future therapies have led opponents of interferon to overlook these results. Based on the available clinical evidence, however, high-dose interferon should be offered as standard care for patients with high-risk, resected melanoma. Informed patients who have elected to forego interferon and patients with lower risk lesions can be offered participation in clinical trials with a no-treatment control arm.

Full access

A Case of Unusual Mast Cell Response With Interstitial Cystitis-Like Symptoms to Neoadjuvant Chemotherapy for Muscle-Invasive Transitional Cell Carcinoma of the Bladder

Venkata Pokuri, Norbert Sule, Yousef Soofi, Bo Xu, Khurshid Guru, and Saby George

Localized bladder cancers constitute approximately 35% of all bladder cancer cases and have an overall 5-year relative survival of 70%. 1 Urothelial (transitional cell) carcinomas are the most common histologic subtype in the United States. Cisplatin

Full access

New First-Line Systemic Treatment Options for Metastatic Esophageal Squamous Cell Carcinoma

Presented by: Michael K. Gibson

For many years, treatment options for patients with metastatic esophageal squamous cell carcinoma (SCC) were few, and survival rates were low. Combination cytotoxic chemotherapy regimens afforded patients roughly another year of survival at most

Full access

Clinical Significance of Histologic Variants of Bladder Cancer

Joshua I. Warrick

Pathologists have identified many bladder cancer (BCA) histomorphologies that differ from conventional urothelial carcinoma (UC; also known as transitional cell carcinoma ). Several of these histologic variants are biologically aggressive, and

Full access

Effectiveness of Initial Transarterial Chemoembolization for Hepatocellular Carcinoma Among Medicare Beneficiaries

Hanna K. Sanoff, YunKyung Chang, Joseph M. Stavas, Til Stürmer, and Jennifer Lund

Background Hepatocellular carcinoma (HCC) is one of a handful of malignancies with increasing incidence and mortality rates in the United States. 1 , 2 HCC has a very poor prognosis, largely because two-thirds of patients have underlying

Full access

Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma

Enrique Soto-Perez-de-Celis, Pedro N. Aguiar Jr, Mónica L. Cordón, Yanin Chavarri-Guerra, and Gilberto de Lima Lopes Jr

Background Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, the sixth most common neoplasm, and the third leading cause of cancer death worldwide. 1 , 2 HCC incidence is highest in Eastern Asia and sub-Saharan Africa

Full access

Therapeutic Delays Lead to Worse Survival Among Patients With Hepatocellular Carcinoma

Amit G. Singal, Akbar K. Waljee, Nishant Patel, Emerson Y. Chen, Jasmin A. Tiro, Jorge A. Marrero, and Adam C. Yopp

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and has an increasing incidence in the United States. 1 Prognosis for patients with HCC largely depends on tumor stage at diagnosis, with curative options

Full access

Development and Validation of a Nomogram for Predicting Postoperative Early Relapse and Survival in Hepatocellular Carcinoma

Yongzhu He, Laihui Luo, Renfeng Shan, Junlin Qian, Lifeng Cui, Zhao Wu, Shuju Tu, WenJian Zhang, Wei Lin, Hongtao Tang, Zeyu Huang, Zhigang Li, Shengping Mao, Hui Li, Zemin Hu, Liping Liu, Wei Shen, Kun He, and Yong Li

Background Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver, and its incidence is increasing worldwide. 1 – 3 Although liver resection is the main treatment for HCC, high tumor recurrence after surgery remains a